CN112210516B - Lactobacillus helveticus L1258 with intestinal regulation function and composition thereof - Google Patents
Lactobacillus helveticus L1258 with intestinal regulation function and composition thereof Download PDFInfo
- Publication number
- CN112210516B CN112210516B CN202011116363.3A CN202011116363A CN112210516B CN 112210516 B CN112210516 B CN 112210516B CN 202011116363 A CN202011116363 A CN 202011116363A CN 112210516 B CN112210516 B CN 112210516B
- Authority
- CN
- China
- Prior art keywords
- parts
- lactobacillus
- component
- lactobacillus helveticus
- helveticus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 240000002605 Lactobacillus helveticus Species 0.000 title claims abstract description 66
- 235000013967 Lactobacillus helveticus Nutrition 0.000 title claims abstract description 66
- 229940054346 lactobacillus helveticus Drugs 0.000 title claims abstract description 66
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 230000000968 intestinal effect Effects 0.000 title abstract description 16
- 230000033228 biological regulation Effects 0.000 title description 4
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 35
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 35
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 35
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 35
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 35
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 35
- 235000013305 food Nutrition 0.000 claims abstract description 27
- 238000004321 preservation Methods 0.000 claims abstract description 24
- 238000009629 microbiological culture Methods 0.000 claims abstract description 8
- 244000005700 microbiome Species 0.000 claims abstract description 8
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 23
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 23
- 229960003451 lactitol Drugs 0.000 claims description 23
- 235000010448 lactitol Nutrition 0.000 claims description 23
- 239000000832 lactitol Substances 0.000 claims description 23
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 23
- 241000207199 Citrus Species 0.000 claims description 19
- 229920001202 Inulin Polymers 0.000 claims description 19
- 235000020971 citrus fruits Nutrition 0.000 claims description 19
- 239000000835 fiber Substances 0.000 claims description 19
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 19
- 229940029339 inulin Drugs 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 14
- 229940050549 fiber Drugs 0.000 claims description 2
- 241000253411 Albibacter helveticus Species 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 44
- 230000001105 regulatory effect Effects 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 18
- 230000004064 dysfunction Effects 0.000 abstract description 10
- 230000002906 microbiologic effect Effects 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 4
- 206010012735 Diarrhoea Diseases 0.000 description 29
- 206010010774 Constipation Diseases 0.000 description 18
- 241000894006 Bacteria Species 0.000 description 17
- 230000013872 defecation Effects 0.000 description 13
- 239000000843 powder Substances 0.000 description 13
- 230000006870 function Effects 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 7
- 230000003385 bacteriostatic effect Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 241000607598 Vibrio Species 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000006041 probiotic Substances 0.000 description 6
- 235000018291 probiotics Nutrition 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000006477 desulfuration reaction Methods 0.000 description 5
- 230000023556 desulfurization Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000036649 Dysbacteriosis Diseases 0.000 description 3
- 208000027244 Dysbiosis Diseases 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000007140 dysbiosis Effects 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 201000004384 Alopecia Diseases 0.000 description 2
- 208000000412 Avitaminosis Diseases 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 206010021135 Hypovitaminosis Diseases 0.000 description 2
- 206010025476 Malabsorption Diseases 0.000 description 2
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 2
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000002052 colonoscopy Methods 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 208000030401 vitamin deficiency disease Diseases 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 102000040350 B family Human genes 0.000 description 1
- 108091072128 B family Proteins 0.000 description 1
- 241000605059 Bacteroidetes Species 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 241000605716 Desulfovibrio Species 0.000 description 1
- 206010012742 Diarrhoea infectious Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 206010015993 Eyelid oedema Diseases 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 102000002419 Motilin Human genes 0.000 description 1
- 101800002372 Motilin Proteins 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000605861 Prevotella Species 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000004840 megacolon Diseases 0.000 description 1
- 201000003102 mental depression Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001543 purgative effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229940075620 somatostatin analogue Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention belongs to the technical field of microorganisms, and provides lactobacillus helveticus L1258 with an intestinal tract adjusting function, which is preserved in China general microbiological culture collection center of microbiological research institute of China academy of sciences in 9, 8 and 2020, with the preservation number of CGMCC No.20611, the preservation address of which is as follows: the composition of No. 3 of No.1 Xin Xilu of Chaoyang district, Beijing comprises 5-10 parts of Lactobacillus helveticus L1258, 4-8 parts of Lactobacillus acidophilus La28 and 6-9 parts of Lactobacillus plantarum LP 45. The composition can be used for preparing food for regulating intestinal tract and improving intestinal tract dysfunction; through the technical scheme, the problem that the effect of the microecologics on regulating intestinal flora disturbance in the prior art is not good enough is solved.
Description
Technical Field
The invention belongs to the technical field of microorganisms, and relates to lactobacillus helveticus L1258 with an intestinal tract adjusting function and a composition thereof.
Background
Intestinal dysfunction is a general term for a group of gastrointestinal syndromes and seriously affects the quality of life of patients. Some patients may even be dare or unable to work normally due to the frequent abdominal pain and diarrhea. Repeated diarrhea irritation to the intestinal mucosa can cause lesions in the intestinal mucosa, such as the conversion to ulcerative colitis and even cachexia. It can also lead to anemia, malabsorption of nutrients and vitamin deficiency. The deficiency of energy supply can lead people to feel dizziness, fatigue of limbs, dry mouth and tongue, palpitation and short breath. The skin and hair are dry due to vitamin deficiency, the hair loses normal luster and moisture, and the phenomena of alopecia and premature baldness are caused. The absorption of hematopoietic materials is reduced, which can cause anemia, dizziness, tinnitus, fatigue, asthenia, and inattention. Intestinal dysfunction can also cause constipation, and researches on culturing feces of adult chronic constipation patients show that the number of bifidobacteria and lactobacilli is obviously reduced, and the number of potential pathogenic bacteria is increased. In recent years, the 16S rRNA high-throughput sequencing technology is researched to find that the diversity of the fecal flora of children with chronic constipation is different from that of healthy children, the firmicutes/bacteroidetes (F/B) value of the children with chronic constipation is higher than that of the healthy children, the number of Prevotella in a chronic constipation group is obviously reduced, and the number of several genera in the firmicutes is obviously increased. Intestinal dysfunction is largely related to temporary or persistent dysbacteriosis, and human intestinal tract inhabits more than 400 kinds of bacteria, and the normal flora of the intestinal tract mainly consists of beneficial bacteria, harmful bacteria and neutral bacteria. By "dysbacteriosis", it is meant that the balance of the intestinal flora deviates from the potentially beneficial or healthy beneficial bacteria, but instead shifts to an increase in harmful bacteria.
Existing approaches to intestinal regulation include (1) probiotics: the microecological preparations such as the golden bifidobacterium, the lizhu intestinal tract and the like can adjust the balance of human intestinal microecology, reform the disordered flora structure, improve the non-specific immune function of an organism, inhibit the excessive proliferation of intestinal bacteria and the generation and release of endotoxin, increase the tolerance of the organism, synthesize various vitamins and organic acids in the intestinal tract, promote the absorption of the human body on proteins and vitamins, supplement various amino acids and trace elements, improve the nutritional status, promote appetite and help digestion; (2) antibiotics: antibiotics can kill bacteria, and many people still use antibiotics to condition the intestinal tract. It can also cause dysbacteriosis, leading to vitamin B family and K deficiency; can also cause superinfection, such as pseudomembranous enteritis, acute hemorrhagic enteritis, candida infection, etc. Lincomycin and clindamycin cause the most common pseudomembranous enteritis, followed by cephalosporins iv and V. Acute hemorrhagic enteritis is mainly caused by semi-synthetic penicillin, and the incidence rate caused by ampicillin is the highest; (3) the somatostatin analogue can enhance gastrointestinal absorption function and inhibit gastrointestinal hormone (motilin) with strong diarrhea-causing effect, and can effectively reduce diarrhea frequency and amount and improve nutrient malabsorption.
The microecological preparation is widely used for regulating the intestinal tract because of the outstanding advantages, but the existing bacterial strain still has the defect of insufficient effect of regulating the intestinal tract flora disorder.
Disclosure of Invention
The invention provides Lactobacillus helveticus L1258 with an intestinal tract adjusting function and a composition thereof, and solves the problem that a microecological preparation in the prior art has an insufficient effect of adjusting intestinal tract flora disorder.
The technical scheme of the invention is realized as follows: the Lactobacillus helveticus L1258 with intestinal tract regulating function is deposited in China general microbiological culture Collection center of microbiological research institute of China academy of sciences at 9-8.2020, with the preservation number of CGMCC No.20611, and the preservation addresses are as follows: xilu No.1 Hospital No. 3, Beijing, Chaoyang, North.
The composition of the Lactobacillus helveticus L1258 with the intestinal tract regulating function comprises, by mass, 5-10 parts of Lactobacillus helveticus L1258, 4-8 parts of Lactobacillus acidophilus (Lactobacillus acidophilus) La28, 6-9 parts of Lactobacillus plantarum (Lactobacillus plantarum) LP45, wherein the preservation number of the Lactobacillus acidophilus La28 is CGMCC No.11506, and the preservation unit is: the general microorganism strain preservation center of China Committee for culture Collection of microorganisms has the preservation address of No. 3 Xilu No.1 Beijing north Zhongyang district, the institute of microbiology of China academy of sciences, the preservation date of 2015 10 and 15 days, and the Lactobacillus plantarum LP45 is preserved in 26 8 and 26 days of 2013 in the general microorganism strain preservation center of China Committee for culture Collection of microorganisms with the preservation numbers of: CGMCC No.8072, the preservation address is: xilu No.1 Hospital No. 3, Beijing, Chaoyang, North.
Further, the composition comprises 8 parts by weight of lactobacillus helveticus L1258, 7 parts by weight of lactobacillus acidophilus La28 and 8 parts by weight of lactobacillus plantarum LP 45.
Application of a composition of lactobacillus helveticus L1258 with intestinal tract regulating function in preparing food for regulating intestinal tract and improving intestinal tract dysfunction is provided.
Further, the food comprises a component A and a component B in parts by weight; the component A comprises 5-10 parts of lactobacillus helveticus L1258, 4-8 parts of lactobacillus acidophilus La28 and 6-9 parts of lactobacillus plantarum LP45, and the component B comprises citrus fiber and inulin.
Further, the food comprises a component A and a component B in parts by weight; the component A comprises 5-10 parts of lactobacillus helveticus L1258, 4-8 parts of lactobacillus acidophilus La28, and 6-9 parts of lactobacillus plantarum LP45, and the component B comprises citrus fiber, inulin, and lactitol and/or stachyose.
Further, the food comprises a component A and a component B in parts by weight; the component A comprises 5-10 parts of lactobacillus helveticus L1258, 4-8 parts of lactobacillus acidophilus La28 and 6-9 parts of lactobacillus plantarum LP45, and the component B comprises 0.5-1.0 part of lactitol, 1-2 parts of stachyose, 10-20 parts of citrus fiber and 4-10 parts of inulin.
Further, the food comprises the following components in parts by mass: 6, a component A and a component B; the component A comprises 8 parts of lactobacillus helveticus L1258, 7 parts of lactobacillus acidophilus La28 and 8 parts of lactobacillus plantarum LP45, and the component B comprises 0.7 part of lactitol, 1.5 parts of stachyose, 16 parts of citrus fiber and 9 parts of inulin.
Further, the mass ratio of the component A to the component B is 1: (5-8).
The working principle and the beneficial effects of the invention are as follows:
1. the invention provides a Lactobacillus helveticus L1258 strain, which is preserved in China general microbiological culture Collection center of the institute of microbiology, China academy of sciences, China Committee of microbiological culture Collection, in 9, 8 and 2020, with the preservation number of CGMCC No.20611 and the preservation address of: the diameter of a bacteriostatic zone for inhibiting intestinal tract aggregation Escherichia coli EAEC is 16.63mm, the diameter of a bacteriostatic zone for inhibiting desulfurization vibrio is 19.65mm, the lactobacillus helveticus L1258 is compounded with lactobacillus plantarum LP45 and lactobacillus acidophilus La28, the composition is combined with auxiliary matching of a component B, the composition is used for improving constipation, the composition is taken for 7 days, the total effective rate reaches 80%, the composition is taken for 14 days, the total effective rate reaches 96.67%, the composition is used for treating diarrhea of mice, the average curing time of the first diarrhea is 6.0h, the incidence rate of the second diarrhea is 0%, the effect of improving diarrhea and constipation is fast to take effect, the effects of improving diarrhea and constipation are obviously improved, and the intestinal flora is effectively improved and adjusted.
2. In the component A, the lactobacillus helveticus L1258, the lactobacillus plantarum LP45 and the lactobacillus acidophilus La28 are compounded and cooperate to inhibit the diameter of an inhibition zone of intestinal tract aggregated escherichia coli EAEC from 21.03-21.11mm and the diameter of an inhibition zone of desulfurization vibrio from 26.43-26.58mm, so that the inhibition effect of the lactobacillus helveticus L1258 on escherichia coli and desulfurization vibrio is improved.
3. According to the invention, through the compound design of the component A and the auxiliary matching of the lactitol, the stachyose, the citrus fiber and the inulin in the component B, the composition is taken for 7 days, the total effective rate reaches 80%, the total effective rate reaches 14 days, the total effective rate reaches 96.67%, the composition is used for treating the diarrhea of mice, the average curing time of the first diarrhea is 6.0h, and the incidence rate of the second diarrhea is 0%, wherein the component B adopts the compound of the lactitol, the stachyose, the citrus fiber and the inulin, and the taking effect of the probiotics on constipation and diarrhea is improved.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention. The preservation number of lactobacillus acidophilus La28 is CGMCC No.11506, and the preservation unit is as follows: the general microbiological center of China Committee for culture Collection of microorganisms, the preservation address is No. 3 of Xilu No.1 on North Chen of the rising area in Beijing, the microbiological research institute of Chinese academy of sciences, the preservation date is 2015, 10 months and 15 days; the lactobacillus plantarum LP45 was deposited in the China general microbiological culture Collection center (CGMCC) at 26.8.2013, with the following deposition numbers: CGMCC No.8072, the preservation address is: xilu No.1 Hospital No. 3, Beijing, Chaoyang, North; the Lactobacillus helveticus L1258 is classified and named as Lactobacillus helveticus (Lactobacillus helveticus), is preserved in China general microbiological culture Collection center of the institute of microbiology, China academy of sciences, China Committee of microbiological culture Collection, with the preservation number of CGMCC No.20611, and the preservation address is as follows: xilu No.1 Hospital No. 3, Beijing, Chaoyang, North.
First, an embodiment
Example 1
A composition of lactobacillus helveticus L1258 with intestinal regulation function comprises, by mass, 8 parts of lactobacillus helveticus L1258, 7 parts of lactobacillus acidophilus La28 and 8 parts of lactobacillus plantarum LP 45.
Example 2
A composition of Lactobacillus helveticus L1258 with an intestinal tract regulating function comprises, by mass, 10 parts of Lactobacillus helveticus L1258, 4 parts of Lactobacillus acidophilus La28, and 9 parts of Lactobacillus plantarum LP 45.
Example 3
A composition of Lactobacillus helveticus L1258 with an intestinal tract regulating function comprises, by mass, 5 parts of Lactobacillus helveticus L1258, 8 parts of Lactobacillus acidophilus La28 and 6 parts of Lactobacillus plantarum LP 45.
Example 4
A composition of lactobacillus helveticus L1258 with an intestinal tract regulating function comprises, by mass, 9 parts of lactobacillus helveticus L1258, 5 parts of lactobacillus acidophilus La28 and 7 parts of lactobacillus plantarum LP 45.
Example 5
A composition of lactobacillus helveticus L1258 with an intestinal tract regulating function comprises, by mass, 9 parts of lactobacillus helveticus L1258, 7 parts of lactobacillus acidophilus La28 and 8 parts of lactobacillus plantarum LP 45.
Example 6
The only difference compared to example 1 is that only lactobacillus helveticus L1258 is included.
Comparative example 1
The only difference compared to example 1 is that only lactobacillus plantarum LP45 was included.
Comparative example 2
Compared to example 1, the only difference is that only lactobacillus acidophilus La28 is included.
Comparative example 3
Compared to example 1, the only difference is that lactobacillus acidophilus La28 was not included.
Comparative example 4
The only difference compared to example 1 is that Lactobacillus plantarum LP45 was not included.
Escherichia coli is the most main pathogen of diarrhea pathogen spectrum, accounting for 40.31% of all diarrhea cases, desulfovibrio is highly related to constipation, intestinal disorders include these two harmful bacteria, so the lactobacillus of examples 1-5 and comparative examples 1-4 are used as target bacteria to perform the following target bacteria in vitro bacteriostasis experiment:
after the vibrio desulfurizate is activated for three generations, 1X 10 is used8The desulfurization vibrio with the concentration of CFU/mL is coated on a fresh Columbia blood plate, immediately placed into an Oxford cup, added with 100 mu L of each target bacterium to be detected, and fixed for 1h under the microaerobic condition. After culturing for 72h, measuring the diameter of the bacteriostatic ring; after the Escherichia coli is activated for three generations, 1 × 10 is used8Escherichia coli with CFU/mL concentration was spread on a fresh blood plate containing no antibiotic TBS medium, immediately placed in an Oxford cup, 100. mu.L of each target bacterium to be tested was added, and fixed under microaerobic conditions for 1 hour. After 72h of incubation, the results of measuring the diameter of the zone of inhibition are given in table 1 below.
TABLE 1 in vitro bacteria inhibition experiment of Lactobacillus in examples 1 to 6 and comparative examples 1 to 4
From the data in the above table, it can be seen that the total amount of the target bacteria added in the target extracellular bacteriostatic test is the same, the lactobacillus helveticus L1258 is only used in example 6, the lactobacillus plantarum LP45 or the lactobacillus acidophilus La28 is used alone in comparative examples 1-2, the diameter of the bacteriostatic circle of the comparative examples 1-2 is reduced, and the lactobacillus helveticus L1258 and the lactobacillus plantarum LP45 or the lactobacillus acidophilus La28 are compounded in comparative examples 3-4, which is not much different from the diameter of the bacteriostatic circle of example 6, so that the compounding of the lactobacillus helveticus L1258 and the lactobacillus plantarum LP45 or the lactobacillus acidophilus La28 does not improve the bacteriostatic effect of the lactobacillus helveticus L1258.
Compared with the two-strain compound preparation adopted in the comparative examples 1-2, the diameter of the inhibition zone of the three-strain compound preparation adopted in the examples 1-5 is obviously increased, the diameter of the inhibition zone for inhibiting intestinal tract aggregation Escherichia coli EAEC is 21.03-21.11mm, and the diameter of the inhibition zone for inhibiting desulfurization vibrio is 26.43-26.58mm, so that the three-strain compound preparation synergistically improves the inhibition effect of Lactobacillus helveticus L1258.
Second, application example
Application example 1
A composition containing Lactobacillus helveticus L1258 with intestinal tract regulating effect is used for preparing food for regulating intestinal tract and improving intestinal tract dysfunction;
the food comprises the following components in parts by mass: 6, a component A and a component B; the component A comprises 8 parts of lactobacillus helveticus L1258, 7 parts of lactobacillus acidophilus La28 and 8 parts of lactobacillus plantarum LP45, and the component B comprises 0.7 part of lactitol, 1.5 parts of stachyose, 16 parts of citrus fiber and 9 parts of inulin.
The food can be made into powder, granule, emulsion, tablet, block, rod, oral liquid or capsule according to requirement, and the preparation method can be conventional method; the food formulation of the application embodiment adopts powder spraying and drying, and the specific conditions are that the high pressure pump pressure is 13-19Mpa, the air inlet temperature is 162-171 ℃, the air exhaust temperature is 77-82 ℃, the temperature in the tower is 88-95 ℃, and the negative pressure in the tower is 109-148 Pa.
Application example 2
A composition containing Lactobacillus helveticus L1258 with intestinal tract regulating effect is used for preparing food for regulating intestinal tract and improving intestinal tract dysfunction;
the food comprises the following components in parts by mass: 5, a component A and a component B; the component A comprises 10 parts of lactobacillus helveticus L1258, 4 parts of lactobacillus acidophilus La28 and 9 parts of lactobacillus plantarum LP45, and the component B comprises 0.5 part of lactitol, 2 parts of stachyose, 10 parts of citrus fiber and 10 parts of inulin.
The food formulation of the application example is prepared into granules, and the specific preparation method of the formulation can adopt the conventional means.
Application example 3
A composition containing Lactobacillus helveticus L1258 with intestinal tract regulating effect is used for preparing food for regulating intestinal tract and improving intestinal tract dysfunction;
the food comprises the following components in parts by mass: 8, a component A and a component B; the component A comprises 5 parts of lactobacillus helveticus L1258, 8 parts of lactobacillus acidophilus La28 and 6 parts of lactobacillus plantarum LP45, and the component B comprises 1.0 part of lactitol, 1 part of stachyose, 20 parts of citrus fiber and 4 parts of inulin.
The food preparation formulation of the application embodiment is prepared into emulsion, and the preparation method of the specific formulation can adopt the conventional means.
Application example 4
A composition containing Lactobacillus helveticus L1258 with intestinal tract regulating effect is used for preparing food for regulating intestinal tract and improving intestinal tract dysfunction;
the food comprises the following components in parts by mass: 6, a component A and a component B; the component A comprises 9 parts of lactobacillus helveticus L1258, 5 parts of lactobacillus acidophilus La28 and 7 parts of lactobacillus plantarum LP45, and the component B comprises 0.6 part of lactitol, 1.2 parts of stachyose, 15 parts of citrus fiber and 5 parts of inulin.
The food dosage form of the application example is prepared into tablets, and the specific preparation method of the dosage form can adopt conventional means.
Application example 5
A composition containing Lactobacillus helveticus L1258 with intestinal tract regulating effect is used for preparing food for regulating intestinal tract and improving intestinal tract dysfunction;
the food comprises the following components in parts by mass: 8, a component A and a component B; the component A comprises 9 parts of lactobacillus helveticus L1258, 7 parts of lactobacillus acidophilus La28 and 8 parts of lactobacillus plantarum LP45, and the component B comprises 0.7 part of lactitol, 1.8 parts of stachyose, 16 parts of citrus fiber and 4 parts of inulin.
The food preparation formulation of the application embodiment is prepared into oral liquid, and the specific preparation method can adopt conventional means.
Application example 6
The difference compared to application example 1 is only that the B component is not included.
Application example 7
The difference compared to application example 1 was only that no lactitol was added.
Application example 8
Compared to application example 1, the difference is only that no stachyose is added.
Application example 9
The only difference compared to application example 1 was that lactitol and stachyose were not added.
Constipation trying clothes
The samples of application example 1 and application examples 6 to 9 were used for trial, and the trial method was as follows:
1. general data: selecting 150 people meeting the grouping conditions, wherein the longest disease course is 11 years, the shortest disease course is half a year, and the disease course is randomly divided into five groups: in the first experimental group, 30 patients were administered with the powder prepared in example 1, in the second experimental group, 30 patients were administered with the powder prepared in example 6, in the third experimental group, 30 patients were administered with the powder prepared in example 7, in the fourth experimental group, 30 patients were administered with the powder prepared in example 8, and in the fifth experimental group, 30 patients were administered with the powder prepared in example 9.
2. And (3) inclusion standard: age 18-60 years; the constipation Roman III standard is met; the course of the disease is at least half a year; the gastrointestinal tract power is not influenced by taking the medicine within nearly one week; diagnosing IBS under-rationale; colonoscopy or colonoscopy eliminates intestinal organic lesions and constipation caused by systemic disease; approximately march satisfies two or more of the following symptoms: firstly, at least 25% of defecation feels hard, secondly, at least 25% of defecation is dry spherical defecation or hard defecation, thirdly, at least 25% of defecation has inexhaustible feeling, thirdly, at least 25% of defecation has anorectal obstruction feeling, and fifthly, the defecation frequency is less than 3 times per week.
3. Exclusion criteria: constipation caused by other diseases and drugs, such as Parkinson's disease, megacolon and patients taking analgesics for a long time; partial functional constipation, such as proctosoma, pelvic spasm syndrome, etc.; those with poor compliance due to alcohol addiction, drug abuse and mental factors; those with chronic abuse of purgative agents. If the gastrointestinal tract power medicine (such as enema) is used by the patient by self during the observation period, the observation is abandoned by self, and the like, the observation is stopped.
4. The administration scheme is as follows:
the application examples 1 and 6-9 samples were taken in the first experiment group, the second experiment group, the third experiment group, the fourth experiment group and the fifth experiment group respectively, and the subjects took the samples with warm water before breakfast each day, 5g of powder each time, and continuously took the samples for 14 days.
5. Observation index and score
During the trial period, the subject is required to fill out a trial condition record table every day according to the self condition. The symptoms before and after the patient takes the test are used as a contrast, the improvement degree of the defecation condition of the patient is compared, and quantitative scoring is carried out according to the defecation condition of the patient.
Observation indexes are as follows: the number of defecation times, defecation index, defecation time, stool hardness and defecation sensation score criteria before and after treatment of the patient are compared and shown in table 2.
TABLE 2 Scoring criteria
6. Trial results
The study completed 150 trial servings, except 2 in the five groups did not insist on taking, the other 148 subjects insist on taking.
Effective rate ═ 100% (pre-treatment score-post-treatment score)/pre-treatment score%
The obvious effect standard is as follows: the effective rate is more than or equal to 60 percent
The effective standard is as follows: 20 percent to less than 60 percent of effective rate
Invalidation criteria: the effective rate is less than or equal to 20 percent
The total effective rate is significant efficiency + effective rate.
TABLE 3 Constipation curative effects
As can be seen from table 3 above, the total effective rate of the powder prepared in application examples 1, 6-9 of the present invention is 66.67-80% after being taken for 7 days, and the total effective rate is 73.33-96.67% after being taken for 14 days. After 3 months of follow-up, the constipation condition of the significant population in the experiment group I is not worsened, and the relapse and worsening conditions of different degrees exist in the experiment groups II to five. Therefore, the powder applied to the embodiment 1 of the invention has better effect of improving constipation;
the component B is not added in the application example 6, and compared with the application example 6, the total effective rate of the application example I is higher, so that the component B promotes the colonization of probiotics in intestinal tracts and effectively regulates the balance of intestinal flora.
The component B in the application example 1 is compounded by adopting lactitol, stachyose, citrus fiber and inulin, the component B in the application example 7 does not adopt lactitol, the component B in the application example 8 does not adopt stachyose, and the component B in the application example 9 does not adopt lactitol and stachyose, but compared with the administration effect of the powder prepared in the application examples 7-9, the total effective rate in 7 days is improved, and the total effective rate in 14 days is improved, so that the compounding of the lactitol and the stachyose with the citrus fiber and the inulin in the application example 1 synergistically improves the administration effect of the probiotic bacteria agent.
Diarrhea test
The samples of examples 1 to 9 were used in the present invention to conduct experiments for the treatment and prevention of acute diarrhea in mice.
First, 100 mice (5 weeks old) with similar body weight and health condition were selected and randomly divided into 10 groups, and 10 groups of mice were infected with intestinal tract-aggregating Escherichia coli EAEC to develop diarrhea symptoms, which are the criteria for infectious diarrhea symptoms: the mice have the disadvantages of mental depression, lassitude, reduced food consumption, reversed hair, abdominal respiration, red and swollen eyelids with secretion, yellow and loose stool. In addition to normal feeding, the first 9 groups were fed with samples of application examples 1-9 with distilled water 1: 3 9 nutrient solutions mixed and shaken up, group 10 using distilled water as a control group, each group was fed 2 times a day, the time of diarrhea healing (healing time was calculated as twice the longest healing time in this experiment if the mice died) was observed, the healing criteria: abdominal respiration disappears, eyelid symptoms disappear, stool forms, and activity and diet are normal. The recovered mice were continuously fed for another 1 month, and the mice were observed for excretion to count the incidence of reinfection diarrhea or other diseases. The results are shown in Table 4 below.
TABLE 4 diarrhea test efficacy
As can be seen from table 4 above, when the powder prepared in application example 1 is used for treating diarrhea in mice, the average time for the first diarrhea to cure is 6.0 hours, and the incidence rate of the second diarrhea is 0%.
In application example 1, the component B is compounded by lactitol, stachyose, citrus fiber and inulin, in application example 7, the component B is not lactitol, in application example 8, the component B is not stachyose, in application example 9, the component B is not lactitol and stachyose, and in application example 1, compared with the administration effect of the powder prepared in application examples 7-9, the average time for curing the first diarrhea and the incidence rate of the second diarrhea are reduced, so that the lactitol and the stachyose are compounded with the citrus fiber and the inulin in application example 1, and the administration effect of the probiotic bacteria agent is synergistically improved.
In addition, the component B is not added in the application example 6, compared with the application example 6, the average time for curing the first diarrhea and the incidence rate of the second diarrhea in the application example 1 are lower, and therefore, the component B promotes the colonization of probiotics in the intestinal tract and effectively regulates the balance of the intestinal flora.
The present invention is not limited to the above preferred embodiments, and any modifications, equivalent substitutions, improvements, etc. within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (9)
1. Lactobacillus helveticus (A. helveticus) (A. helveticus)Lactobacillus helveticus) L1258, wherein the strain is preserved in China general microbiological culture Collection center of China Committee for culture Collection of microorganisms of institute of China academy of sciences at 9/8/2020, with a preservation number of CGMCCNo.20611, wherein the preservation address is as follows: xilu No.1 Hospital No. 3, Beijing, Chaoyang, North.
2. The composition of lactobacillus helveticus L1258 is characterized in that the composition comprises, by mass, 5-10 parts of lactobacillus helveticus L1258 and 4-8 parts of lactobacillus acidophilus (lactobacillus helveticus L1258)Lactobacillus acidophilus) La28, 6-9 parts of lactobacillus plantarum (L.) (Lactobacillus plantarum) LP45, the preservation number of the Lactobacillus helveticus L1258 is CGMCC No.20611, the preservation number of the Lactobacillus acidophilus La28 is CGMCC No.11506, and the preservation number of the Lactobacillus plantarum LP45 is CGMCC No.CGMCC No.8072。
3. The composition of lactobacillus helveticus L1258 according to claim 2, characterized in that it comprises 8 parts by mass of lactobacillus helveticus L1258, 7 parts by mass of lactobacillus acidophilus La28, 8 parts by mass of lactobacillus plantarum LP 45.
4. Use of a composition of lactobacillus helveticus L1258 according to claim 2 in the preparation of a food product.
5. The use of the composition of lactobacillus helveticus L1258 according to claim 4, characterized in that said food comprises, in parts by mass, a component a and a component B; the component A comprises 5-10 parts of lactobacillus helveticus L1258, 4-8 parts of lactobacillus acidophilus La28 and 6-9 parts of lactobacillus plantarum LP45, and the component B comprises citrus fiber and inulin.
6. The use of the composition of lactobacillus helveticus L1258 according to claim 5, characterized in that said food comprises, in parts by mass, a component a and a component B; the component A comprises 5-10 parts of lactobacillus helveticus L1258, 4-8 parts of lactobacillus acidophilus La28, and 6-9 parts of lactobacillus plantarum LP45, and the component B comprises citrus fiber, inulin, and lactitol and/or stachyose.
7. The use of the composition of lactobacillus helveticus L1258 according to claim 6, characterized in that said food comprises, in parts by mass, a component a and a component B; the component A comprises 5-10 parts of lactobacillus helveticus L1258, 4-8 parts of lactobacillus acidophilus La28 and 6-9 parts of lactobacillus plantarum LP45, and the component B comprises 0.5-1.0 part of lactitol, 1-2 parts of stachyose, 10-20 parts of citrus fiber and 4-10 parts of inulin.
8. The use of the composition of lactobacillus helveticus L1258 according to claim 7, characterized in that the food comprises, in parts by mass, 1: 6, a component A and a component B; the component A comprises 8 parts of lactobacillus helveticus L1258, 7 parts of lactobacillus acidophilus La28 and 8 parts of lactobacillus plantarum LP45, and the component B comprises 0.7 part of lactitol, 1.5 parts of stachyose, 16 parts of citrus fiber and 9 parts of inulin.
9. The use of a composition of lactobacillus helveticus L1258 according to any of claims 5 to 7, wherein the mass ratio of the a component and the B component is 1: (5-8).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011116363.3A CN112210516B (en) | 2020-10-19 | 2020-10-19 | Lactobacillus helveticus L1258 with intestinal regulation function and composition thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011116363.3A CN112210516B (en) | 2020-10-19 | 2020-10-19 | Lactobacillus helveticus L1258 with intestinal regulation function and composition thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112210516A CN112210516A (en) | 2021-01-12 |
| CN112210516B true CN112210516B (en) | 2022-05-20 |
Family
ID=74055792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011116363.3A Active CN112210516B (en) | 2020-10-19 | 2020-10-19 | Lactobacillus helveticus L1258 with intestinal regulation function and composition thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112210516B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112877233B (en) * | 2021-01-23 | 2021-12-10 | 江苏斯卡露生物科技有限公司 | Lactobacillus helveticus strain and application thereof |
| CN116515684B (en) * | 2023-03-29 | 2024-03-01 | 微康益生菌(苏州)股份有限公司 | Probiotic agent for improving hyperphosphatemia and application thereof |
| CN116790448B (en) * | 2023-08-21 | 2024-01-12 | 新益(天津)生物科技有限责任公司 | Lactobacillus helveticus OPB102 capable of relieving constipation and diarrhea and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107118981A (en) * | 2017-04-28 | 2017-09-01 | 广东格物生物科技有限公司 | A kind of probiotics preparation and its application for being used to nurse one's health enteric microorganism environment |
| JP2019116423A (en) * | 2017-12-26 | 2019-07-18 | 森永乳業株式会社 | Composition for intestinal regulation |
| CN111254087A (en) * | 2019-12-27 | 2020-06-09 | 杭州娃哈哈科技有限公司 | Lactobacillus helveticus with high adhesion performance and function of enhancing immunity and application thereof |
-
2020
- 2020-10-19 CN CN202011116363.3A patent/CN112210516B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107118981A (en) * | 2017-04-28 | 2017-09-01 | 广东格物生物科技有限公司 | A kind of probiotics preparation and its application for being used to nurse one's health enteric microorganism environment |
| JP2019116423A (en) * | 2017-12-26 | 2019-07-18 | 森永乳業株式会社 | Composition for intestinal regulation |
| CN111254087A (en) * | 2019-12-27 | 2020-06-09 | 杭州娃哈哈科技有限公司 | Lactobacillus helveticus with high adhesion performance and function of enhancing immunity and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 瑞士乳杆菌对感染大肠杆菌O157∶H7小鼠肠道微生物区系的影响;王婷婷等;《食品工业》;20141231;第35卷(第9期);摘要 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112210516A (en) | 2021-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112210516B (en) | Lactobacillus helveticus L1258 with intestinal regulation function and composition thereof | |
| CN110101722B (en) | Application of composite probiotic preparation in preparation of product for treating ulcerative colitis | |
| EP2315582B1 (en) | Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions | |
| US8246946B2 (en) | Treatment of bipolar disorder utilizing anti-fungal compositions | |
| CN112746034B (en) | Lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR519 for synergistically inhibiting helicobacter pylori and application thereof | |
| TW201032733A (en) | Compositions comprising probiotic and prebiotic components and mineral salts, with lactoferrin | |
| CN115074274B (en) | Lactic acid bacteria-containing composition and use thereof | |
| CN111972670A (en) | Composition for relaxing bowel, solid beverage and application | |
| CN110893194B (en) | New application of bifidobacterium lactis BL-99 in inhibiting intestinal inflammation | |
| CN110692885A (en) | Probiotic health-care beverage for relieving constipation | |
| CN110917174A (en) | Oral probiotic capsule for regulating balance of female vaginal flora and preparation method thereof | |
| CN114774315B (en) | Application of lactobacillus rhamnosus strain LRa05 in preparation of immunity enhancing product and/or eczema relieving product | |
| CN112617207A (en) | A composition containing rehydration salt and probiotic bacteria | |
| CN116200305A (en) | Enterococcus durans strain with anti-inflammatory property, culture method and application | |
| CN114287633B (en) | Probiotic composition containing cranberry and application thereof in helicobacter pylori resistance | |
| CN115969957A (en) | Compound probiotic preparation for inflammatory bowel diseases and preparation method thereof | |
| CN113750113B (en) | Composition of probiotics and prebiotics and application thereof | |
| Lazarenko et al. | Imunobiotics are the novel biotech drugs with antibacterial and immunomodulatory properties | |
| CN115119940A (en) | Application of Lactobacillus acidophilus LA85 and Bifidobacterium lactis BLA80 in inhibiting helicobacter pylori | |
| CN110604748A (en) | Application of probiotics and emblic leafflower fruit extract in improvement of diabetes and metabolic syndrome | |
| KR102000170B1 (en) | Food compositions for reducing body fat and improving intestinal function | |
| CN116396884A (en) | Lactobacillus rhamnosus and a composition for inhibiting helicobacter pylori | |
| CN114191447A (en) | Application of hyaluronic acid and salt thereof in improving intestinal flora disorder and composition thereof | |
| CN111603489A (en) | Microbial inoculum for improving constipation and preparation method thereof | |
| CN116790402B (en) | Bacteroides simplex strain with anti-inflammatory property, culture method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 050800 No. 16, bangxiu East Road, North District, high tech Industrial Development Zone, Zhengding County, Zhengding District, China (Hebei) pilot Free Trade Zone, Shijiazhuang City, Hebei Province Applicant after: Hebei Yiran Biotechnology Co.,Ltd. Address before: 050899 No.16, bangxiu East Road, Zhengding high tech Development Zone, Shijiazhuang City, Hebei Province Applicant before: HEBEI INATURAL BIOTECHNOLOGY Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |